Kyowa Kirin Co., Ltd.
Research Kyowa Kirin Co., Ltd. (4151.T) on Bullrun: market cap JPY 1.23T, P/E 15.1, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4151.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 1.23T
- P/E15.1
- Dividend yield2.8%
- Financial periodFY2025
- RevenueJPY 496.83B
- Revenue growth0.3%
- Net incomeJPY 67.04B
- Free cash flowJPY 5.40B
- Gross margin74.2%
Valuation Snapshot
latest market cap is JPY 1.23T; P/E is 15.1; dividend yield is 2.8%.
Peer valuation comparison
Latest P/E is 15.07x versus a Healthcare sector median of 21.69x (30.5% below).
Latest dividend yield is 2.82% versus a Healthcare sector median of 2.41% (17.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 496.83B | JPY 67.04B | JPY 5.40B | 74.2% | 128.07 | JPY 218.77B | n/a | JPY 893.33B |
| FY2024 | JPY 495.56B | JPY 59.87B | -JPY 37.38B | 73.2% | 113.06 | JPY 244.68B | n/a | JPY 850.81B |
| FY2023 | JPY 442.23B | JPY 81.19B | JPY 82.70B | 74.9% | 151.01 | JPY 403.08B | n/a | JPY 836.42B |
| FY2022 | JPY 398.37B | JPY 53.57B | JPY 20.01B | 78.2% | 99.66 | JPY 339.19B | n/a | JPY 762.83B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 1.23T | 15.1 | 3.0% | 70 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 70 JPY, yield 2.8%.
| Year | Dividends/share |
|---|---|
| FY2025 | 62 JPY |
| FY2024 | 58 JPY |
| FY2023 | 56 JPY |
| FY2022 | 51 JPY |
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kyowa Kirin Co., Ltd.'s market cap?
Kyowa Kirin Co., Ltd.'s market capitalization is JPY 1.23T.
What is Kyowa Kirin Co., Ltd.'s P/E ratio?
Kyowa Kirin Co., Ltd.'s price-to-earnings (P/E) ratio is 15.1.
Does Kyowa Kirin Co., Ltd. pay a dividend?
Kyowa Kirin Co., Ltd. has a dividend yield of 2.8%.
What does Kyowa Kirin Co., Ltd. do?
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis.